The primary analysis in two-arm clinical trials usually involves inference on a scalar treatment effect parameter; e.g., depending on the outcome, the difference of treatment-specific means, risk difference, risk ratio, or odds ratio. Most clinical trials are monitored for the possibility of early stopping. Because ordinarily the outcome on any given subject can be ascertained only after some time lag, at the time of an interim analysis, among the subjects already enrolled, the outcome is known for only a subset and is effectively censored for those who have not been enrolled sufficiently long for it to be observed. Typically, the interim analysis is based only on the data from subjects for whom the outcome has been ascertained. A goal of an interim analysis is to stop the trial as soon as the evidence is strong enough to do so, suggesting that the analysis ideally should make the most efficient use of all available data, thus including information on censoring as well as other baseline and time-dependent covariates in a principled way. A general group sequential framework is proposed for clinical trials with a time-lagged outcome. Treatment effect estimators that take account of censoring and incorporate covariate information at an interim analysis are derived using semiparametric theory and are demonstrated to lead to stronger evidence for early stopping than standard approaches. The associated test statistics are shown to have the independent increments structure, so that standard software can be used to obtain stopping boundaries.
翻译:在两股临床试验中进行的初步分析通常涉及对标度处理效果参数的推断;例如,根据结果、具体治疗方法的差异、风险差异、风险比率或胜率比率,对多数临床试验进行监测,以确定及早停止的可能性。由于通常任何特定主题的结果只有在经过一段时间后才能确定,因此在临时分析时,在已经注册的学科中,结果只针对一个子类,对那些没有登记足够长的时间来观察结果的临床试验者有效审查。通常,临时分析仅以已确定结果的学科的数据为依据。临时分析的目标是,一旦证据足够充分,一旦证据足够充分,可以及早停止审判,即停止试验试验,因此,分析最好能最有效地利用所有现有数据,从而在临时分析时,包括关于审查和其他基线的信息,并以有原则的方式根据时间变数计算结果。为临床试验提出一个一般小组顺序框架,以时间滞后的结果为准。考虑到审查和纳入共同变量的治疗效果估测结果,一旦证据足够强大,临时分析的目标是一旦证据足够充分时,即停止审判,即停止试验,在试验结构上显示采用较强的试验标准,可以采用较强的软件。